Metformin decreases RAN proteins, rescues splicing abnormalities and improves behavioral phenotypes in SCA8 BAC mice
Authors:
- Lisa E.L RomanoLRLisa E.L Romano
- Setsuki TsukagoshiSTSetsuki Tsukagoshi
- Emily E. Davey-OsuchEDEmily E. Davey-Osuch
- Ramadan AjrediniRARamadan Ajredini
- Kamat ManasiKMKamat Manasi
- Tala V.R. OrtizTOTala V.R. Ortiz
- Eduardo RijosEREduardo Rijos
- Nathan J. BourgonNBNathan J. Bourgon
- S. Elaine AmesSAS. Elaine Ames
- Timothy J. GarrettTimothy J. Garrett
- John D. ClearyJCJohn D. Cleary
- Eric T. WangEWEric T. Wang
Preprint
Abstract
Spinocerebellar ataxia type 8 is one member of a larger group of dominantly inherited, debilitating neurological diseases caused by CTG*CAG expansions for which there are no effective disease-targeting treatments. RAN translation, which was discovered in SCA8, has previously been shown to occur across CAG and CUG expansion transcripts, making treatments that work for SCA8 potentially relevant to a much broader group of diseases, including SCA1, 2, 3, 6, 7, 12, Huntington’s Disease (HD) Fuch’s endothelial corneal dystrophy (FECD), and myotonic dystrophy type 1 (DM1). The FDA-approved drug, metformin, has been previously shown to reduce RAN protein levels in cells overexpressing SCA8 CAG repeats. Here we show, using SCA8 BAC transgenic mice, that metformin treatment improves ambulatory performance, including rotarod, DigiGait, and open field measures. At the molecular level, metformin-treated mice show reduced RAN protein levels and improved splicing abnormalities without changing the levels of the expanded RNAs. Metformin-treated mice also show decreased neuroinflammation with reduced levels of astrogliosis and reduced numbers of activated microglia. Taken together, these data provide strong support for testing FDA-approved metformin in clinical trials for SCA8 and potentially the broader group of CAG*CTG repeat expansion disorders. One Sentence Summary: Metformin improves behavior, neuropathological and molecular phenotypes in SCA8 BAC transgenic mice.Keywords
This publication has 68 references indexed in Scilit:
- Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal NeurodegenerationCellular and Molecular Neurobiology, 2024
- Metformin alleviates reactive gliosis and neurodegeneration, improving cognitive deficit in a rat model of temporal lobe epilepsyBrain Research, 2024
- Mutation and clinical analysis of the CLCC1 gene in amyotrophic lateral sclerosis patients from Central South ChinaAnnals of Clinical and Translational Neurology, 2023
- Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicingLife Sciences, 2022
- Antisense Oligonucleotide Therapy: From Design to the Huntington Disease ClinicBioDrugs, 2022
- RAN proteins in neurodegenerative disease: Repeating themes and unifying therapeutic strategiesCurrent Opinion in Neurobiology, 2022
- NFIB Haploinsufficiency Is Associated with Intellectual Disability and MacrocephalyThe American Journal of Human Genetics, 2018
- Metformin: From Mechanisms of Action to TherapiesCell Metabolism, 2014
- CTCF Regulates Ataxin-7 Expression through Promotion of a Convergently Transcribed, Antisense Noncoding RNANeuron, 2011
- Metformin therapy in a transgenic mouse model of Huntington's diseaseNeuroscience Letters, 2007